On July 22, Sino Biopharmaceutical rose 3.13% in regular trading, trading at 5.24 HKD/share with turnover of 95.48 million HKD, rebounding swiftly after a 3.09% decline in the prior session.

The pharmaceutical sector broadly recovered, with CSPC Pharma up 0.36%, Hansoh Pharma up 1.84%, and Hengrui Pharma up 1.59%. The company has accumulated multiple positive catalysts in recent weeks: on July 14, its subsidiary's TRD205 (AT2R antagonist) received Breakthrough Therapy Designation from China's CDE for chronic painful peripheral neuropathy; on July 10, the NDA for IDH1 inhibitor TQB3454 targeting advanced biliary tract cancer was accepted by regulators and entered priority review; on July 8, the company signed an exclusive licensing agreement with AstraZeneca for TQC3721, a PDE3/4 inhibitor for COPD, with total consideration of up to $1.9 billion including a $200 million upfront payment, while simultaneously deepening its strategic partnership with GSK in respiratory therapeutics. Multiple brokerages maintain Buy ratings, with target prices of 8.70 HKD and 7.70 HKD respectively.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)